There’s No Out For The Allergan Deal, Teva CEO Says
This article was originally published in The Pink Sheet Daily
The only thing standing in the way of Teva’s acquisition of Allergan’s generic drug business is antitrust issues, the firm said, after Allergan confirmed it is in merger discussions with Pfizer.
You may also be interested in...
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.